[This review was originally posted at the Nieman Journalism Lab Order Synthroid, on June 1, 2012.]
Debating the meaning of Facebook’s IPO flop: Facebook’s fall following its initial public offering two weeks ago continued this week, with shares dropping under $30 (they were initially offered at $38). Several other social media-based companies have seen their stock tank, too, prompting Forbes’ Dee Gill to wonder if Facebook’s IPO has been a reminder that “even a wildly popular product won’t save a company that can’t make money.”
David Strom of ReadWriteWeb did point out, though, that stock prices soon after tech IPOs haven’t been a very reliable indicator of companies’ prospects for long-term success. The New York Times’ Joe Nocera made a similar point, arguing that Facebook’s IPO flop was fueled by get-rich-quick investors and that long-term investors should be undeterred, Synthroid treatment.
At PandoDaily, Farhad Manjoo made the case that Facebook’s IPO was a valuable corrective to a dangerously overhyped tech market: “Facebook’s IPO proves that there isn’t an endless supply of bigger suckers. And because bigger suckers are the primary ingredients in bubbles, it now seems likely that the new tech bubble—if there ever was one—is dead, dead, dead.” And The Atlantic’s Alexis Madrigal made a pretty thorough defense of Facebook’s value as a company, Synthroid forum, reminding us that it has a still-growing near-monopoly and tremendous potential for making money from its millions of users.
There was still plenty of criticism of Facebook floating around this week, though, Order Synthroid. The New York Times’ Ross Douthat saw Facebook as a sign of the lack of financial progress brought by the Internet economy, and Facebook’s advertising shortcomings continued to be a point of discussion. Ad Age reported that GM pulled its advertising from Facebook in part because Facebook balked at its proposal to run full-page ads, which, according to media consultant Terry Heaton, illustrated the difference between Madison Avenue’s philosophy of bending the masses to their will and Facebook’s gentler approach. The Huffington Post’s Bianca Bosker also looked at the tension Facebook is facing between its advertisers and users, Synthroid maximum dosage.
Here at the Lab, Dan Kennedy extended the ad problem to journalists, proposing a few ideas for adapting to an online world in which the value of ads continues to shrink. Order Synthroid, Also on the news front, Buzzfeed’s John Herrman wrote about how coverage on Twitter of the Facebook IPO indicates that Twitter is well ahead of Facebook in covering and developing breaking stories.
Another major note on Facebook to keep an eye on: The New York Timesreported that the company is trying again to build a smartphone to release later this year. It’s had several false starts in this area before, but is moving “deeper into the process” this time. Is Synthroid addictive, Facebook was also reported this week to be buying the facial recognition company Face.com.
The impact of New Orleans’ move away from print: As we moved into the second week of discussion of the New Orleans Times-Picayune’s cutback from daily newspaper production, the conversation began to shift from New Orleans in particular to the future of the newspaper industry as a whole. Poynter’s Steve Myers looked at a couple of the immediate issues — concerns over whether Advance Publications’ other papers (such as the Cleveland Plain Dealer) might make similar cuts, and whether New Orleans readers are likely to follow their paper online, Order Synthroid.
The New York Times’ David Carr, who broke the story, wrote a kind of elegy for the paper, concluding that while the cutback may make some financial sense, it’s a great loss for a historically corrupt city. “The constancy of a paper, ordering Synthroid online,” he wrote, “is a reminder to a city that someone is out there watching.” At the Huffington Post, Harry Shearer thought Carr wasn’t harsh enough in his assessment of Advance’s plans, arguing that breaking readers’ daily newspaper habits is foolish, not economical. Shearer, Synthroid wiki, Myers, and Iowa journalist Dave Schwartz all pointed out that New Orleans has particularly low Internet penetration rates (not to mention high newspaper penetration rates), with Schwartz calling those without web access “casualties in a revolution.”
Mathew Ingram of GigaOM and CUNY prof Jeff Jarvis, on the other hand, both argued that we need to get past our fixation with print journalism, using it when it’s profitable but feeling free to drop it when it’s not. “We have to make print beside the point,” Jarvis wrote, Synthroid without prescription. Will Bunch of the Philadelphia Daily News, meanwhile, proposed some ideas at Poynter for resolving the journalism crisis in New Orleans, focusing on philanthropic efforts to improve Internet access, hyperlocal journalism, and accountability journalism. Al Jazeera discussed the future of the newspaper industry Order Synthroid, in light of New Orleans’ move away from daily with a few luminaries as well. Synthroid dangers,
While Postmedia CEO Paul Godfrey complained in an interview with the Globe & Mail that its ad revenue was being stolen by foreign digital companies (read: Google, AOL, etc.), GigaOM’s Mathew Ingram said the problems for Postmedia and other newspapers run much deeper than cuts and paywalls. Synthroid street price, Crain’s Chicago Business also reported that the Chicago Tribune is considering a paywall potentially focusing on niche coverage, and Poynter’s Steve Myers pointed out that the major newspaper companies that aren’t charging for news are quickly becoming the outliers.
The paywall debate got a shot in the arm this week in the aftermath of the Times-Picayune’s cuts, when The Wire creator and former newspaper reporter David Simon asserted at the Columbia Journalism Review that “the whole industry will continue to collapse until everyone swallows hard and goes behind a paywall.”The short post spurred a feisty comment thread as well as several varying responses, Order Synthroid. A post at the news startup Circa made a distinction between charging for content (OK) and information (much more difficult to do), and Will Bunch made his aforementioned philanthropically driven proposals for New Orleans as a middle way between paywall advocates and detractors.
In addition, former newspaper editor John L. Robinson argued that if young people won’t even pay much for Facebook, they sure won’t pay for a newspaper — and that should worry newspaper publishers, Synthroid class. Here at the Lab, Ken Doctor added some practical approaches to the discussion, looking at the effectiveness of different newspapers’ plans to shift from advertiser revenue toward reader revenue.
Mathew Ingram of GigaOM echoed the idea, and meanwhile, Technically Philly’s Sean Blanda and blogger Dave Winer both wrote on rethinking the elements of an article — Blanda proposed thinking of the basic unit of journalism as the fact rather than the article, and Winer said we need to do better than Wikipedia when it comes to background information and explainers, Order Synthroid.
— WikiLeaks’ Julian Assange lost his appeal to the British Supreme Court against extradition to Sweden on accusations of a pair of 2010 sexual abuse cases. No prescription Synthroid online, He has two weeks to appeal one of the ruling’s points, but it looks as though he’s headed to Sweden to stand trial. Here’s The Guardian’s and The New York Times’ coverage, and Micah Sifry’s examination of the state of online whistleblowing as WikiLeaks struggles.
— A couple of ebook notes: Amazon settled its dispute Order Synthroid, with a publisher that pulled its books from the site earlier this year, and meanwhile, two other publishers filed responses to the Department of Justice’s antitrust suit on ebook pricing, and Apple filed its response to a parallel class-action suit.
— Web designer Oliver Reichenstein ripped the ubiquitous “Share” buttons all over news and other sites, while the Lab’s Joshua Benton provided some initial data showing they may be quite helpful for news orgs to prompt sharing of their content on Twitter.
— Cornell prof Tarleton Gillespie wrote an interesting post exploring whether we can trust Twitter’s Trending Topics algorithm, and GigaOM’s Mathew Ingram said it’s not necessarily Twitter’s job to broaden our worldview, Synthroid dose, but instead our own responsibility.
— Finally, it’s not shameless self-promotion if it’s actually really good: The Lab ran several fascinating pieces this week that are worth a look — Justin Ellis’ talk with Guardian editor Alan Rusbridger, some cool ideas for improving news from MIT Media Lab students courtesy of Andrew Phelps, and the AP’s Jonathan Stray’s smart column on broadening our concept of what journalists do. Enjoy.
Similar posts: Tramadol Cost. Glucophage Over The Counter. Diflucan Dosage. Bactrim price. Tramadol without a prescription. Tramadol overnight.
Trackbacks from: Order Synthroid. Order Synthroid. Order Synthroid. Buy Synthroid online cod. Synthroid pharmacy. Is Synthroid safe.
[This review was originally posted at the Nieman Journalism Lab Diflucan For Sale, on May 4, 2012.]
Parliament’s damning News Corp. report: It was a second straight week of big news in News Corp.’s phone hacking case, as a committee of the British Parliament issued its report on the scandal (PDF), in which the major statement was that Rupert Murdoch is “not a fit person” to run an international media empire like News Corp. The report also targeted three News Corp. executives in particular — former Dow Jones headLes Hinton, former News of the World editor (and current New York Daily News editor) Colin Myler, and former News International lawyer Tom Crone — for their roles in the scandal’s cover-up, Diflucan steet value. The three may be forced to apologize to Parliament.
The New York Times and Guardian both offered good overviews of the report, with the Times focusing more on Murdoch and the Guardian on Hinton, Myler, and Crone, Diflucan For Sale. Both noted that the strong language about Murdoch was decided along political lines, with liberals voting to put it in and conservatives trying to keep it out. Capital’s Tom McGeveran wrote a helpful explanation of what it means for Parliament to call Murdoch “unfit” (he probably won’t get his broadcast licenses revoked anytime soon), and NPR’s David Folkenflik also had a good breakdown of the situation for American audiences. One of the committee’s members, Buy Diflucan without prescription, Tom Watson, offered more of his own thoughts on the scandal, and the Times’ David Carr translated the report for those of us who don’t read Parliament-ese.
News Corp. Diflucan For Sale, responded by issuing a defiant public statement, which contrasted a bit with Murdoch’s more contrite internal memo. Other businesspeople and media barons came to Murdoch’s defense, and the British broadcaster BSkyB, of which News Corp. owns a share and recently tried to take over, about Diflucan, distanced itself from News Corp. in an effort to hang onto its broadcast license.
There’s other trouble for News Corp., too: A Washington ethics group has called on the FCC to revoke News Corp.’s Fox broadcast licenses in the U.S., and in Britain, opponents of News Corp.’s BSkyB takeover bid said they had been blocked from meeting with the government department in charge of approving the deal. There is some good news for News Corp., Diflucan alternatives, though — the second half of the British government’s inquiry into the company may never happen.
As for the toll on News Corp., the Times has a solid big-picture view of the scandal’s impact so far, and Reuters’ Jack Shafer looked at the escape routes Murdoch could take, Diflucan For Sale. The Columbia Journalism Review’s Ryan Chittum said this report, and Murdoch’s testimony last week, have gone a long way in exposing News Corp.’s culture of corruption: “The glib denials that have served him so well for so many years aren’t working anymore—not with all we now know.” And the Guardian’s Henry Porter went further, writing the (probably premature) political obit for Murdoch.
Mixed signals on newspaper circulation: The Audit Bureau of Circulations issued its twice-annual report on newspaper circulation this week — here are its top 25 papers and a database of every daily newspaper in the U.S. Overall, newspapers saw a slight gain in daily circulation, Diflucan price, including a 63 percent gain in paid digital circulation, which, as paidContent noted, includes tablet or smartphone apps, paywalled website subscriptions, and other e-editions. Buy Diflucan from mexico, The common narrative drawn from those numbers was that, as Ad Age put it, “digital paywall strategies have helped newspapers counter years of grinding declines in paid-print circulation.” Poynter’s Steve Myers looked at some of the top circulation gainers and saw that many of them had instituted digital pay plans, while very few of the losers had.
Media analyst Alan Mutter pushed back Diflucan For Sale, against that conclusion, noting that when you isolate print circulation, almost everyone’s numbers were down, whether they had a paywalled site or not. The circulation increase, it turns out, came from including those digital numbers (and, as Ad Age pointed, possibly counting subscribers twice), not from successfully protecting the print product.
A few newspapers that were highlighted: DCist noted that The Washington Post’s circulation drop was the largest of any of the nation’s top papers, while Poynter’s Andrew Beaujon said the decline wasn’t as bad as it appeared. J-prof Dan Kennedy looked at the numbers for the Boston papers, and the Lab’s Justin Ellis wrote about the story behind the Minneapolis Star Tribune’s increase in circulation and revenue, and its paywall.
Is tech in another bubble?: New York Times tech writer Nick Bilton became the latest to raise the specter of a bubble in the tech industry this week, where can i find Diflucan online, reporting on the practice of startups being encouraged by their investors not to make money so as to make it easier to come up with ungrounded, outrageously high valuations. Said one Stanford professor he talked to: “This is 1999 all over again, but this time, it’s gotten worse…We’re back to companies throwing around funny money. The economic values don’t add up.”
This started another round of debate over whether we are, Diflucan mg, in fact, in the midst of another tech bubble. BetaBeat put together a helpful scorecard of who chimed in on which side, and you can read a smart, extended discussion among many of those people at Branch, Diflucan For Sale. Tech blogger Dave Winer said the true sign of whether we’re in a bubble is whether the startups being formed are good businesses that make sense and will grow (and answered that, yes, that means we’re in a bubble).
Investor and blogger Chris Dixon argued that the true measures of a bubble are actually quite nuanced, and we’re getting mixed signals in many of them, though he said no good investors engage in the “flipping” practices Bilton described, japan, craiglist, ebay, overseas, paypal, because it’s not a good business strategy anyway. Tech blogger MG Siegler agreed, calling stories like Bilton’s “a bunch of vague fear mongering.” GigaOM’s Mathew Ingram said it appears as though the inflated valuations are coming in at the small, early seed-money end, which presents less of a danger to the public. Entrepreneur Michael Mace made a similar point, Cheap Diflucan, arguing that until those inflated dollar amounts hit public stock offerings, this market won’t look much like the late ’90s bubble.
Mathew Ingram of GigaOM argued that while the update is an improvement, Twitter still needs to build better filters to personalize and make sense of its information, before others do it instead. YouTube’s Hunter Walk pointed out, buy Diflucan no prescription, though, that it’s extremely hard for a single product to guess at what you like, what your friends like, and what the world likes, especially in a linear format like Twitter’s.
Elsewhere in Twitter news, After Diflucan, the Lab’s Adrienne LaFrance wrote about journalistic behavior by regular Twitter users, and news execs argued over whether social media is helping or hurting journalism.
— The FCC voted last Friday to require local TV stations to put their information about political advertising online, starting in the largest markets. Free Press applauded the decision as a victory for transparency, though ProPublica noted they won’t be searchable. Before the vote, Poynter’s Steve Myers pointed out how resistant TV stations have been to reporting on this issue, Diflucan no rx.
— As The Next Web first reported this week, the Washington Post planned to buy the social news site Digg. That report was followed up with reports that the Post was hiring most of Digg’s staff Diflucan For Sale, , but not buying the site or its technology, leaving the remaining people there to scramble to figure out the site’s future.
— In an engaging book excerpt in New York magazine, Jeff Himmelman revealed that Watergate hero Bob Woodward’s longtime editor at the Washington Post, Ben Bradlee, had misgivings about some of the details about some of the sources Woodward and Carl Bernstein contacted, Diflucan price, coupon, including Deep Throat. Woodward disputed the book’s claims, Himmelman defended them, and the Post’s Erik Wemple said he was skeptical of the reports of Bradlee’s doubts, too. Reuters’ Jack Shafer pointed out that this conflict is only about the All the President’s Men story, not the Post’s actual reporting.
— Two great posts of tips for journalists: Poynter’s Craig Silverman with a list of resources on how to verify information on social media, buy Diflucan online no prescription, and the Guardian’s advice for journalists of the future.
— Finally, Danish scholar Rasmus Kleis Nielsen wrote an insightful piece for Reuters based on some ongoing research he’s doing on what’s hindering news startups in Europe. He calls it “irrational imitation” of the dominant online model of decades past.
Similar posts: Buy Armour No Prescription. Purchase Lipitor. Flagyl Mg. Bactrim photos. Effects of Retin A. Where can i buy Synthroid online.
Trackbacks from: Diflucan For Sale. Diflucan For Sale. Diflucan For Sale. Diflucan coupon. Diflucan no prescription. Comprar en línea Diflucan, comprar Diflucan baratos.
[This review was originally posted at the Nieman Journalism Lab Buy Armour No Prescription, on April 13, 2012.]
Facebook scoops up Instagram: There were two billion-dollar deals in the tech world this week, and by far the bigger of the two was Facebook’s purchase of the photo-sharing app Instagram. Mathew Ingram of GigaOM has a good, quick roundup of initial reaction to the deal, but I’ll try to sort through each of the angles to the story, including what this means for Facebook, Instagram, and the tech world in general. Buy Armour online cod, The first big question was why Facebook bought Instagram, especially for so much money. The most common answer, voiced most persuasively by GigaOM’s Om Malik, was that Facebook felt threatened by Instagram’s ascendance in mobile photo sharing, one area in which Facebook has struggled. Business Insider’s Nicholas Carlson explained why Instagram does mobile photos so much better than Facebook, and Fortune’s Dan Primack suggested that Facebook panicked at all the money Instagram has raised recently, Armour maximum dosage.
The New York Times also characterized the deal as a big move by Facebook into mobile media, but there were other key aspects at work, too: Ingram said Instagram’s value lay in its network, and Wired’s Tim Carmody said what matters to Facebook is Instagram’s personal data, Buy Armour No Prescription. Rackspace’s Robert Scoble outlined some of the specifics of that data, and All Things Digital’s Lauren Goode focused on Instagram’s location data. New York’s Paul Ford said Facebook is attempting to buy Instagram’s sincerity: “Remember what the iPod was to Apple. That’s how Instagram might look to Facebook: an artfully designed product that does one thing perfectly.”
So what does this mean for Instagram. TechCrunch detailed the company’s rise, and the big concern was, Ordering Armour online, as CNN’s John Sutter put it, whether Facebook would “ruin” Instagram. Mashable’s Christina Warren urged Facebook Buy Armour No Prescription, to keep Instagram mobile-only and keep it separate from Facebook logins, and Jolie O’Dell of VentureBeat pointed out some of the good things Facebook’s developers could do for Instagram. TechCrunch noted that Facebook’s statement that it would keep Instagram as a separate product is a big departure from Facebook’s unified approach.
That concern over Facebook ruining Instagram indicates a certain revulsion for Facebook among Instagram users, something Om Malik took note of. Forbes’ John McQuaid said the sentiments reveal our uneasiness with the utility-like role tech giants like Facebook are playing in our new social world, and The Next Web’s Courtney Boyd Myers reminded Instagram users that the fact that they loved it so much was a big part of the reason it got bought in the first place.
The next question was for the tech industry as a whole: Does Instagram’s massive purchase price signal another tech market bubble, online Armour without a prescription. The Atlantic’s Rebecca Greenfield said it’s just time to accept the existence of a social media bubble, and the Guardian’s Charles Arthur said we may not be at the peak of inflated valuations, though also at the Guardian, Dan Gillmor said we could be near the end of the bubble, Buy Armour No Prescription. But Wired’s Andy Baio crunched the numbers and said Instagram wasn’t overvalued, and if anything, the tech market is rewarding efficiency. Forbes’ Robert Hof, meanwhile, looked at whether we’ll see more social media purchases soon, Armour schedule, coming up with some reasons for a slowdown.
Finally, Poynter’s Jeff Sonderman looked at some of the ways journalists have used Instagram, and Reuters’ Jack Shafer put the deal in the context of the larger cultural shift from voice to text to images. “So, Instagram is here,” he said. “What I want to know is: Where is it going to take us?”
Buy Armour No Prescription, Apple, publishers, Amazon, and ebooks’ future: The ebook industry absorbed a blow this week when the U.S. Department of Justice sued Apple and five of the largest book publishers for antitrust violations involving price-fixing for ebooks, cheap Armour. (Sixteen states also filed a lawsuit of their own.) Three of the publishers — Hachette, Simon & Schuster, and HarperCollins — immediately settled with the DOJ, and Wired’s Tim Carmody explained the terms of the settlement, which will undermine the model that the publishers created with Apple, though not kill it outright. Armour duration, Apple, Penguin, and Macmillan have decided not to settle, and the latter’s CEO issued a defiant letter in response to the suit.
PaidContent’s Laura Hazard Owen wrote a fantastic explanation of what the case is about, but in short, the issue centers on what’s called agency pricing, in which the publishers set book prices, Armour blogs, rather than the retailers, and the books must be at the same price across retailers. In 2010, Apple negotiated an agency pricing model with the big book publishers for the rollout of its iPad’s iBookstore, and the DOJ objected to that as price-fixing, Buy Armour No Prescription.
The Verge’s Nilay Patel dug through more of the details from the lawsuit of the alleged price-fixing process, particularly its response to Amazon’s perceived ebook dominance. At the same time, however, Buy generic Armour, as Peter Kafka of All Things Digital noted, Apple was allegedly considering a deal to divide and share rulership over online content with Amazon. A few people said the DOJ wasn’t likely to win the suit: Law prof Richard Epstein said the agency pricing arrangement has more social and consumer benefits than a classic collusion case, and CNET concluded that Apple should be able to win its case, too. Adam Thierer of the Technology Liberation Front put the strategy in the context of copyright challenges, coming out against the suit in the process. Buy Armour No Prescription, Also this week, we found out that several of the big publishers have refused to sign their annual contracts with Amazon, as Salon’s Alexander Zaitchik reported and Laura Hazard Owen explained. The Seattle Times has been running a critical series on Amazon, Armour gel, ointment, cream, pill, spray, continuous-release, extended-release, which, as the Los Angeles Times pointed out, includes some real concern about Amazon behaving anti-competitively by selling ebooks for too little.
Publishers have argued that that’s why agency pricing is necessary: It’s the best chance to keep Amazon from undercutting publishers and laying waste to the book industry. Web thinker Tim O’Reilly said the government should be watching Amazon more closely than the five companies it just sued, but Nate Hoffelder of The Digital Reader defended Amazon, Online buying Armour, arguing that it’s helping enable an entirely new publishing model in its stead.
Christopher Mims of Technology Review said it doesn’t matter if Amazon becomes a monopoly. And GigaOM’s Mathew Ingram also said Amazon’s practices have been good for consumers and good for innovation, unlike those of the publishers: “They seem to have spent most of their time dragging their feet and throwing up roadblocks to any kind of innovation … Their defense of the agency-pricing model feels like yet another attempt to stave off the forces of disruption, Buy Armour No Prescription. Why not try to adapt instead?”
Others had more personal stories: The legendary investigative reporter Seymour Hersh, longtime Philly television columnist Gail Shister, j-prof Dan Kennedy, and The Wrap’s Sharon Waxman, Buy Armour No Prescription. As Kennedy wrote: “I really do think there was a golden age of television news, and Wallace was right in the middle of it.”
— A few more takes on last week’s purchase of the Philadelphia Inquirer and Daily News by a group of local investors: The New York Times’ David Carr mused on the return of the newspaper baron, the American Journalism Review’s John Morton examined the recent spree of newspaper purchases in a downtime for the industry, Purchase Armour online no prescription, and Penn prof Victor Pickard argued for more systemic solutions to save papers like Philly’s.
— A couple of interesting pieces from the academic view of journalism: NYU’s Jay Rosen and MIT’s Ethan Zuckerman talked about trends in journalism at an MIT forum (summarized well by Matt Stempeck), and CUNY’s C.W. Anderson talked a bit about his research on data journalism to Tyler Dukes of Reporters’ Lab.
— The debate over the value of online commenting continues: Animal’s Joel Johnson proposed that comments are worth far less than publishers think, because they don’t draw many readers and don’t make money, but GigaOM’s Mathew Ingram countered that comments are an important check on online authority and that not allowing them tells readers to “go away.”
— News analyst Alan Mutter made the age-old argument that newspapers are failing in their digital efforts in a brief, potent piece decrying newspapers’ poor digital products and weak competitive response, and urging them to pool their efforts.
— Finally, Digital First Media’s Steve Buttry wrote a gracious but no-nonsense letter to newsroom curmudgeons defending digital journalism practices, then wrote about what he learned from its fallout, then addressed the role of news organizations themselves in enabling curmudgeonhood. The posts and comments are a good glimpse into the current state of newsroom culture and change.
Similar posts: Retin A Mg. Buy Diflucan No Prescription. Synthroid For Sale. Discount Glucophage. Get Synthroid. Tramadol pics.
Trackbacks from: Buy Armour No Prescription. Buy Armour No Prescription. Buy Armour No Prescription. Low dose Armour. Order Armour from United States pharmacy. Armour gel, ointment, cream, pill, spray, continuous-release, extended-release.